Skip to main content

Table 4 Clinical-pathological prognostic features of disease

From: Detection methods predict differences in biology and survival in breast cancer patients

 

Prevalent (n = 76) vs. Incident screened (n = 65)

P value

OR

Mean age

56.88 ± 0.65 vs. 59.71 ± 0.68

P < 0.01

0.91 (0.86-0.98)

Mean size (cm)

1.64 ± 0.15 vs. 1.27 ± 0.17

p < 0.05

1.44 (1.01-2.08)

Lymph node positive

25% vs. 21.5%

N.S.

1.21 (0.55-2.66)

Poorly-differentiated tumors

32.1% vs. 32.8%

N.S.

0.96 (0.49-1.90)

ER positive

87.5% vs. 89.1%

N.S.

0.85 (0.27-2.64)

PR positive

70.3% vs. 78.2%

N.S.

0.66 (0.28-1.52)

in situ carcinomas

13% vs. 11%

N.S.

1.25 (0.44-3.51)

Apoptosis

42.5% vs. 66.7%

N.S.

0.37 (0.12-1.11)

Bcl-2

75.4% vs. 81.3%

N.S.

0.70 (0.28-1.77)

Ki67

38.5% vs. 63%

p < 0.01

0.36 (0.17-0.77)

c-erb-B2

7.4% vs. 23%

p < 0.01

0.22 (0.08-0.61)

Delay Diagnosis- treatment (>30 days)

64.5 vs. 35.4

p < 0.01

3.31 (1.65-6.62)